We had the pleasure to talk to Maria Cinta Cid (Hospital Clinic Barcelona, Barcelona, Spain) about the use of mavrilimumab in patients with giant cell arteritis (Clinical Trial Identifier: NCT03827018). The abstract ‘Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis’ (ABSTRACT NUMBER: L06) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- Could you tell us a little about giant cell arteritis, its prognosis and incidence? (0:05)
- What is the current standard of care for giant cell arteritis, and what are the limitations of this treatment? (1:52)
- What is the mechanism of action of mavrilimumab? (6:07)
Disclosure: Maria Cinta Cid discloses receiving consulting/advisory board fees from GSK, Abbvie and Janssen, lecturing fees from Vifor and a research grant from Kiniksa. Maria Cinta Cid was regional lead for the GiACTA trial (Riche) and co-PI for the KPL-301-C001 trial with mavrilimumab.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
